Is Journey Medical Corporation (DERM) a Buy, Sell, or Hold?
Journey Medical Corporation
NASDAQ:DERM
$7.12 USD
$0.26 (3.79%)
- Volume
- 134.38K
- Average Volume
- 270.28K
- Market Capitalization
- $195.95M
- P/E Ratio
- -18.94
- Dividend Yield
- 0.00%
- Price Target
- $11.75
- Year High
- $9.56
- Year Low
- $4.31
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.72
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Claude Maraoui |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Current Symbol | DERM |
| CUSIP | 48115J109 |
| CIK | 0001867066 |
| Web | https://journeymedicalcorp.com |
| Phone | 480 434 6670 |
| Currency | USD |
| Employees | 58 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.83 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.72 |
| Quick Ratio | 1.47 |
| Cash Ratio | 0.72 |
Sales & Book Value
| Annual Sales | $61.86M |
| Price / Sales | 3.03 |
| Cash Flow | -0.25 |
| Price / Cash Flow | -29.25 |
| Price / Book | 6.31 |
Price Target and Rating
| Average Stock Price Forecast | $11.75 |
| High Stock Price Forecast | $13.00 |
| Low Stock Price Forecast | $10.50 |
| Forecast Upside/Downside | -39.40% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.47 |
| Trailing P/E Ratio | -18.94 |
| PEG Ratio | 1.71 |
| P/E Growth | 1.71 |
| Net Income | $-11.43M |
| Net Margin | -14.82% |
| Pretax Margin | -14.73% |
| Return on Equity | -35.57% |
| Return on Assets | -10.47% |
Financials Score
| AltmanZ Score | 1.18 |
| Piotroski Score | 3.00 |
| Working Capital | 27.14M |
| Total Assets | 91.53M |
| Ebit | -5.83M |
| Market Cap | 189.21M |
| Total Liabilities | 60.7M |
Poll Results
About Journey Medical Corporation (NASDAQ:DERM) Stock
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulcon ... azole nitrate cream and solution.
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
2026-05-19 16:45:00
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference, taking place on Wednesday, May 20, 2026. The fireside chat is scheduled to begin at 5:00pm ET.
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
2026-05-13 19:30:47
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates
2026-05-13 18:15:58
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.18 per share a year ago.
2026-05-13 16:01:00
Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi ® revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased to $27 million, driven by strong financial performance Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz.
2026-05-07 10:00:00
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
2026-05-06 16:01:00
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 13, 2026 at 4:30 p.m. ET
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know
2026-05-06 11:01:20
Journey Medical (DERM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2026-04-30 22:40:00
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Frequently Asked Questions
-
What is the current Journey Medical Corporation (DERM) stock price?
-
Journey Medical Corporation(NASDAQ:DERM) stock price is $7.12 in the last trading session. During the trading session, DERM stock reached the peak price of $9.555 while $4.31 was the lowest point it dropped to. The percentage change in DERM stock occurred in the recent session was 3.79% while the dollar amount for the price change in DERM stock was $0.26.
-
DERM's industry and sector of operation?
-
The NASDAQ listed DERM is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of DERM?
-
Robert Nevin | Chief Commercial Officer
Lindsay Allan Rosenwald | Executive Chairman
Jaclyn Jaffe | Senior Director of Corporate Operations
Brian Prout | Executive Director of Marketing
Claude Maraoui | Founder, President, Chief Executive Officer & Director -
How many employees does DERM have?
-
Number of DERM employees currently stands at 58. DERM operates from 9237 East Via de Ventura Boulevard, Scottsdale, AZ 85258, US.
-
Link for DERM official website?
-
Official Website of DERM is: https://journeymedicalcorp.com
-
How do I contact DERM?
-
DERM could be contacted at phone #480 434 6670 and can also be accessed through its website. DERM operates from 9237 East Via de Ventura Boulevard, Scottsdale, AZ 85258, US.
-
How many shares of DERM are traded daily?
-
The average number of DERM shares traded daily for last 3 months was 270.28K.
-
What is the market cap of DERM currently?
-
The market value of DERM currently stands at $195.95M with its latest stock price at $7.12